PE/VC investors

Private Equity (PE) and Venture Capital (VC) investors are the catalysts of innovation and growth in the business world. PE firms primarily target established companies, seeking to optimize operations and unlock value through strategic investments and management expertise. They focus on long-term growth and profitability, often preparing businesses for a future sale or IPO. VC investors, by contrast, are the adventurers of finance, injecting capital into high-potential startups and early-stage companies. They embrace risk for the possibility of outsized returns, often becoming invaluable advisors. Both investor types not only bring capital but also strategic guidance, industry connections, and market insights, propelling their portfolio companies towards success.

Investors (6,250)

Investor

Description

More information

Sun SEA Capital

Sun SEA Capital is a corporate venture capital established and managed by Sunway Group. Startups will be able to leverage on Sunway’s ecosystem and extensive network to achieve sustainable growth.

View

Sunbo Angel Partners

Sunbo Angel Partners (SAP) is a global venture capital firm headquartered in Busan, South Korea, with offices in Ulsan, Gwangju, Seoul, Singapore and Berlin. We strive to provide a platform for open innovation by connecting startups with our corporate alliance of 17 limited partners to create opportunities for business collaboration, joint ventures, co-investment, and merger & acquisition.

View

Sunbridge Partners

SunBridge Partners is all about passion and vision. Passion to make a difference with entrepreneurs, by sharing their vision to change the world. We firmly believe the best way to engage entrepreneurs is to partner with them. Not by sending a check and showing up once a quarter. Not by micromanaging them. Not by parachuting in our favorite CEO to take over. Not by pairing them with a Partner managing 10 other Board seats.

View

Suncorp Group (SUN)

Our purpose is to create a better today for all of our stakeholders; including our customers, shareholders, people and communities. This means we help people live the life they want now and plan for the life they want tomorrow. The Group's goal is to create value for our customers through our portfolio of market-leading brands while benefiting from the efficiencies of scale achievable as a large organisation. The Group is a diversified, simplified, low-risk financial services group that delivers both high yield and above system growth. Our organic growth strategy is based exclusively in Australia and New Zealand.

View

SunFunder

SunFunder is a mission-driven solar finance business based in Nairobi unlocking debt capital for solar energy in emerging markets, where over 2.2 billion people live without access to reliable energy. We offer borrowers a deep solar market expertise, an efficient due diligence process and strong customer partnerships, while simultaneously providing investors with diversified, high-impact, fixed income debt offerings of emerging market solar investments. We have unlocked a total of $62 million for the sector through our Beyond The Grid Solar Fund and other debt facilities. To date we have made over $64 million of loans in 60 debt facilities to 45 solar companies.

View

Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm. Our purpose – and passion – is to seek out, enable and empower the most promising life science therapeutics innovations. We help turn new science into new products, improving outcome for patients. And we help create value for innovators, investors and health care systems around the world. We were founded in 2007 by an international team of industry experts combining entrepreneurial, operational and financial experience. This means we have the experience, the competencies and the networks to carefully select and then fully support our portfolio companies with both funding and business development and more. We are committed to working hands-on with our portfolio companies to build value. We work closely with management and board members and also offer the competencies of our experienced Business Development Board. This board consists of leading international Life Science executives who have all been involved hands-on in licensing, partnerships and M&A’s on the buy-side. We believe that the founder/investor relationship works best when built on a balanced foundation of respect and honesty. Building a successful start-up is rarely a straightforward process, and most companies experience troubles at some point in time. In that situation, everyone is best served by having an honest and collaborative relationship. Sunstone Life Science Ventures focuses on investment opportunities based on novel therapeutics for humans; with strong potential for global success. We typically make our initial investment in companies raising Series A or B rounds, but in some cases even earlier. See more in our Investment Strategy To date, Sunstone Life Science Ventures has invested in more than 45 life science companies and several successful IPOs and large M&A transactions have been completed from our portfolio so far (see below). The road from innovation to market in the life sciences area often demands both large-scale and long-term investments. Accordingly, we more often than not co-invest with other funds and institutional investors. We encourage and welcome both (co-) investors and innovators to contact us to open a dialogue. Investment Strategy & Management Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans. Our geographical scope is Europe including UK with particular emphasis on the European life science hubs. Our point of entry differs depending on the type of opportunity; however, we usually invest when drug candidates are in the pre-clinical or clinical phase I. Sunstone Life Science Ventures’ investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the life science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on the radar of potential acquirers, we invest in opportunities that truly stand out in terms of both science and market positioning. We seek opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. Opportunities aimed at specialty pharma and orphan drug indications are especially interesting to us, and oncology continues to be an important area, for society and for investors alike. We believe that the single most important factor when developing a successful company is the quality of the management team. This does not mean that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company. We are committed to working hands-on with our portfolio companies to build value. In order to do so, Sunstone is represented on the board of directors and works closely with the management team and the other board members to develop the company. As an extra, unique offering, aimed at building the value of our portfolio companies, we offer access to Sunstone’s Business Development Board, established in 2007 and consisting of leading Life Science executives who have all been involved hands-on in licensing, partnerships and M&A’s on the buy-side. Sunstone Life Science Ventures Fund I was established at the inception of Sunstone in 2007. The total committed capital is EUR 200 million. The investment strategy included therapeutics, medical technology and diagnostics. The fund is no longer making new investments. Sunstone Life Science Ventures Fund II was established at the inception of Sunstone in 2007. The total committed capital is EUR 86 million and the fund invested in 12 new portfolio companies. The investment strategy included therapeutics, medical technology and diagnostics. The fund is no longer making new investments. In 2010, Sunstone took over management of the former BankInvest Biotechnology Funds. The funds are no longer making new investments. Sunstone Life Science Ventures Fund III was established in 2012. The total committed capital is EUR 80 million and the fund invested in 11 new portfolio companies. The investment strategy included therapeutics, and medical technology. The fund is no longer making new investments. Sunstone Life Science Ventures Fund IV was established in 2019. The total committed capital is EUR 92 million. The investment strategy is focused entirely on therapeutics. The fund is currently building the portfolio and is actively pursuing new investment opportunities.

View

Sunstone Partners

Sunstone Partners was founded in 2015 and has $800 million of committed capital under its first two funds. We invest in minority and majority transactions. We are entrepreneurs ourselves, so we appreciate and respect the journey of our entrepreneurs and are committed to delivering muscle to their businesses with humility and mutual respect. We are a leading growth oriented private equity firm that makes majority and minority investments in technology-enabled services and software businesses. We seek to partner with exceptional entrepreneurs, often as their first institutional capital partner, to help accelerate organic growth and fund acquisitions. We have over 70 years of collective experience investing and helping technology companies achieve successful outcomes.

View

Sup.vc

SUP VC is an intensive accelerator program that help startups grow and expand to international markets. During 3-month program startups build their products, learn different practices that are applied in international environment and the program is finalized by Demo Day. SUP VC intends to be a melting pot for our startups by providing access to capital, mentorship, customer acquisition and product development. With dozens number of mentorship network across the globe, SUP VC delivers the knowledge, international practice and the best entrepreneurial journey. COMMUNITY Our community is our strength. SUP VC is a connecting hub between startups, international and local mentors & coaches and operating team. MENTORSHIP As a startup team, you'll get access to knowledgeable mentors, among which are successful entrepreneurs, experienced investors, industry experts. BRAND & PR Our local and international media connections help you to position your brand in the market. We feature our startup at different events and social media.. OFFICE We provide our startups with office space that operates 24/7. You'll connect with the brightest minds and the most creative people you can meet in Baku. CONNECTIONS We know everyone in the startup community in this country and a lot of others abroad. Our connections will help you expand your professional network. INVESTMENT As a SUP VC portfolio company you'll have an opportunity to connect with local and international investors in Demo Days and raise investment for your startup.

View

Super Ventures

Super Ventures fund leverages in-depth expertise and extensive ecosystem relationships to selectively invest in promising companies that enhance perception, situational awareness, and power to act — creating computer-mediated “superpowers” through Augmented Reality, unleashing our full potential.

View

Superangel

We invest in the best early-stage teams building world-changing technology. Superangel is founded, run and backed by tech entrepreneurs who know what it takes to build successful companies. We typically invest into Pre-Seed / Seed stage software companies with a ticket size of €50k - €300k. Our investment focus includes but is not limited to AI & Robotics, Mobility & Logistics, and Fintech & SaaS.

View